natgillin/translations-raw huggingface dataset:
Tris–hydrochlorid (2–amino–2-hydroxymethyl–1,3–propandiolhydrochlorid) Natriumchlorid
Tris hydrochloride (2-amino-2-hydroxymethyl-1,3-propanediol hydrochloride) Sodium chloride
Tritanrix HepB anvendes til at vaccinere spædbørn fra seks-ugers-alderen mod difteri, stivkrampe, kighoste og hepatitis B.
Tritanrix HepB is used to vaccinate infants from six weeks of age against diphtheria, tetanus, pertussis (whooping cough) and hepatitis B.
Tritanrix HepB er en hvid, næsten mælkeagtig væske i et hætteglas med 2 dosis (1 ml) eller i et hætteglas med 10 doser (5 ml).
Tritanrix HepB is a white, slightly milky liquid presented in a glass vial for 2 doses (1 ml) or in a glass vial for 10 doses (5 ml).
Tritanrix HepB er en vaccine, som anvendes til børn for at beskytte mod fire sygdomme: difteri, tetanus (stivkrampe), pertussis (kighoste) samt hepatitis B. Vaccinen virker ved at hjælpe kroppen til selv at producere egne beskyttelse (antistoffer) mod disse sygdomme.
Tritanrix HepB is a vaccine used in children to prevent four diseases: diphtheria, tetanus (lockjaw), pertussis (whooping cough) and hepatitis B. The vaccine works by causing the body to produce its own protection (antibodies) against these diseases.
Tritanrix HepB findes i følgende pakningsstørrelser: 1 hætteglas med 2 doser
Tritanrix HepB is available in the following pack sizes: For 2 doses: pack size of 1
Tritanrix HepB indeholder små mængder af:
Tritanrix HepB contains small amounts of:
Tritanrix HepB injektion, suspension
Tritanrix HepB suspension for injection
Tritanrix HepB injektion, suspension, flerdosis
Tritanrix HepB suspension for injection, multidose
Tritanrix HepB kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger.
Like all medicines, Tritanrix HepB can cause side effects, although not everybody gets them.
Tritanrix HepB, injektion, suspension,
Tritanrix HepB, suspension for injection
Tritanrix HepB, suspension til injektion
Tritanrix HepB – Suspension for injection
Tritanrix HepB, suspension, injektion
Tritanrix HepB – Suspension for injection
Tritanrix HepBs udseende og pakningsstørrelse:
What Tritanrix HepB looks like and contents of the pack
TRITANRIX HepBS VIRKNING OG HVAD DU SKAL BRUGE DET TIL
WHAT TRITANRIX HepB IS AND WHAT IT IS USED FOR
Triumeq (dolutegravir/abacavir/lamivudin)-tabletter Hav altid dette kort med dig
Triumeq (dolutegravir / abacavir / lamivudine) tablets Carry this card with you at all times
Triumeq 50 mg/600 mg/300 mg filmovertrukne tabletter
Triumeq 50 mg/600 mg/300 mg film-coated tablets
Triumeq 50 mg/600 mg/300 mg filmovertrukne tabletter dolutegravir/abacavir/lamivudin
Triumeq 50 mg/600 mg/300 mg film-coated tablets dolutegravir/abacavir/lamivudine
Triumeq 50 mg/600 mg/300 mg tabletter dolutegravir/abacavir/lamivudin
Triumeq 50 mg/600 mg/300 mg tablets dolutegravir/abacavir/lamivudine
Triumeq anbefales ikke til brug hos patienter med en kreatininclearance < 50 ml/min (se pkt.
Triumeq is not recommended for use in patients with a creatinine clearance < 50 ml/min (see section 5.2).
Triumeq bør ikke administreres til voksne eller unge, der vejer under 40 kg, da det er en fastdosis- tablet, der ikke kan dosisreduceres.
Triumeq should not be administered to adults or adolescents who weigh less than 40 kg because it is a fixed-dose tablet that cannot be dose reduced.
Triumeq bør kun anvendes under graviditeten, hvis den forventede fordel vejer tungere end den potentielle risiko for fosteret.
Triumeq should be used during pregnancy only if the expected benefit justifies the potential risk to the foetus.
Triumeq eller andre lægemidler med abacavir eller dolutegravir må aldrig påbegyndes igen hos patienter, som er ophørt behandling på grund af en overfølsomhedsreaktion.
After stopping treatment with Triumeq for reasons of a suspected HSR, Triumeq or any other medicinal product containing abacavir or dolutegravir must never be re-initiated.
Triumeq er lilla, bikonvekse, ovale, filmovertrukne tabletter mærket med "572 Trı" på den ene side.
Triumeq film-coated tablets are purple, biconvex, oval tablets, debossed with “572 Trı” on one side.
Triumeq kan tages sammen med eller uden mad (se pkt.
Triumeq can be taken with or without food (see section 5.2).
Triumeq, Trizivir eller Kivexa).
Triumeq,Trizivir or Kivexa).
Triumeqs sikkerhedsprofil forventedes at ligne de enkelte bestanddeles sikkerhedsprofiler og være sammenlignelig med andre hiv-behandlingers sikkerhedsprofil.
Regarding Triumeq’s safety profile, this was expected to be similar to the safety profile of the single components and comparable to that of other HIV treatments.
Trizivir
administration
Trizivir 300 mg/150 mg/300 mg abacavir/lamivudin/zidovudin
Trizivir 300 mg/150 mg/300 mg tablets abacavir/lamivudine/zidovudine
Trizivir 300 mg/150 mg/300 mg filmovertrukne tabletter
TRIZIVIR 300 mg/150 mg/300 mg film-coated tablets
Trizivir 300 mg/150 mg/300 mg filmovertrukne tabletter abacavir/lamivudin/zidovudin
Trizivir 300 mg/150 mg/300 mg film-coated tablets abacavir/lamivudine/zidovudine
Trizivir bør aldrig anvendes til patienter med positiv HLA-B*5701-status, ej heller til patienter med negativ HLA-B*5701-status med tidligere mistanke om en overfølsomhedsreaktion over for et behandlingsregime indeholdende abacavir (f.eks.
Trizivir should never be initiated in patients with a positive HLA-B*5701 status, nor in patients with a negative HLA-B*5701 status who had a suspected abacavir HSR on a previous abacavir-containing regimen. (e.g.
Trizivir filmovertrukne tabletter er mærket “GX LL1” på den ene side.
Trizivir film-coated tablets are engraved with ‘GX LL1’ on one side.
Trizivir indeholder abacavir (som også er det aktive stof i Kivexa, Triumeq og Ziagen).
Trizivir contains abacavir (which is also an active substance in Kivexa, Triumeq and Ziagen).
Trizivir indeholder abacavir (som også er det aktive stof i lægemidlerne Kivexa, Triumeq og Ziagen).
Trizivir contains abacavir (which is also an active substance in medicines such as Kivexa, Triumeq and Ziagen).
Trizivir kan medføre andre bivirkninger i forbindelse med hiv-behandling.
Trizivir may cause other conditions to develop during HIV treatment.
Trizivir kan også forårsage: forhøjet niveau af mælkesyre i blodet, som i sjældne tilfælde kan føre til laktacidose.
Trizivir can also cause: increased levels of lactic acid in the blood, which on rare occasions can lead to lactic acidosis
Trizivir skal seponeres uden forsinkelse, selv hos patienter uden HLA-B*5107 allel, hvis der opstår mistanke om en overfølsomhedsreaktion.
Trizivir must be stopped without delay, even in the absence of the HLA-B*5701 allele, if an HSR is suspected.
Trizivir tabletter findes i uigennemsigtige, hvide PCTFE/PVC-Al-blisterpakninger eller børnesikrede folie PVC/PCTFE/PVC-Al/papir-blisterpakninger med 60 tabletter, eller børnesikrede HDPE- beholdere med 60 tabletter.
Trizivir tablets are available in opaque white PCTFE/PVC-Al blister packs or child-resistant foil PVC/PCTFE/PVC-Al/Paper blister packs containing 60 tablets, or child resistant HDPE bottles containing 60 tablets.
TRIZIVIR TABLETTER OPLYSNINGSKORT (blisterpakning og tabletbeholder)
TRIZIVIR TABLETS ALERT CARD (blister and bottle pack)
Trizivir viste sig at være bioækvivalent med abacavir 300 mg, lamivudin 150 mg og zidovudin 300 mg givet som særskilte tabletter med hensyn til AUC0-∞ og Cmax.
Trizivir was shown to be bioequivalent to abacavir 300 mg, lamivudine 150 mg and zidovudine 300 mg given as separate tablets for AUC0- and Cmax.
Trizivir, Triumeq eller Kivexa).
Trizivir , Triumeq or Kivexa).
Trizivir, Triumeq eller Kivexa).
Trizivir, Triumeq or Kivexa).
Trizivir, Triumeq eller Ziagen), lamivudin eller et af de øvrige indholdsstoffer i dette lægemiddel (angivet i punkt 6)
Trizivir, Triumeq or Ziagen), lamivudine or any of the other ingredients of this medicine (listed in Section 6)
Trizivir, Triumeq eller Ziagen).
Trizivir, Triumeq or Ziagen).
Trizivir, Triumq eller Kivexa).
Trizivir, Triumeq or Kivexa).
Trizivirs sikkerhed og virkning hos børn og unge er ikke klarlagt.
The safety and efficacy of Trizivir in adolescents and children has not been established.
TRM-værdierne varierede fra 0 % til 18 %, hvilket bekræfter sikkerheden ved konditioneringerne med thiotepa til autolog HPCT hos børn med solide tumorer.
TRM values ranged from 0% to 18% confirming the safety of the conditioning treatments including thiotepa for autologous HPCT in paediatric patients with solid tumours.
TRM-værdierne varierede fra 0 % til 21 % efter ét år, hvilket bekræfter sikkerheden ved konditionering med thiotepa til autolog HPCT hos voksne med hæmatologiske sygdomme.
TRM values ranged from 0% to 21% at 1 year, confirming the safety of the conditioning treatment including thiotepa for autologous HPCT in adult patients with haematological diseases.
TRM-værdierne varierede fra 0 % til 30 %, hvilket bekræfter sikkerheden ved den konditionering med thiotepa til allogen HPCT hos børn med hæmatologiske sygdomme.
TRM values ranged from 0% to 30% confirming the safety of the conditioning treatment including thiotepa for allogeneic HPCT in paediatric patients with haematological diseases.
TRM-værdierne varierede fra 0 % til 7,4 %, hvilket bekræfter sikkerheden ved konditioneringen med thiotepa til autolog HPCT hos voksne med solide tumorer.
TRM values ranged from 0% to 7.4% confirming the safety of the conditioning treatment including thiotepa for autologous HPCT in adult patients with solid tumours.
Trobalt 100 mg filmovertrukne tabletter
Trobalt 100 mg film-coated tablets
Trobalt 100 mg filmovertrukne tabletter retigabin
Trobalt 100 mg film-coated tablets retigabine
Trobalt 200 mg filmovertrukne tabletter
Trobalt 200 mg film-coated tablets
Trobalt 200 mg filmovertrukne tabletter retigabin
Trobalt 200 mg film-coated tablets retigabine
Trobalt 300 mg filmovertrukne tabletter
Trobalt 300 mg film-coated tablets
Trobalt 300 mg filmovertrukne tabletter retigabin
Trobalt 300 mg film-coated tablets retigabine
Trobalt 400 mg filmovertrukne tabletter
Trobalt 400 mg film-coated tablets
Trobalt 400 mg filmovertrukne tabletter retigabin
Trobalt 400 mg film-coated tablets retigabine
Trobalt 50 mg filmovertrukne tabletter
Trobalt 50 mg film-coated tablets
Trobalt 50 mg filmovertrukne tabletter er lilla, runde og mærket "RTG 50" på den ene side.
Trobalt 50 mg film-coated tablets are purple, round and marked “RTG 50” on one side.
Trobalt 50 mg filmovertrukne tabletter retigabin
Trobalt 50 mg film-coated tablets retigabine
Trobalt 50 mg filmovertrukne tabletter Trobalt 100 mg filmovertrukne tabletter Trobalt 200 mg filmovertrukne tabletter Trobalt 300 mg filmovertrukne tabletter Trobalt 400 mg filmovertrukne tabletter Retigabin
Trobalt 50 mg film-coated tablets Trobalt 100 mg film-coated tablets Trobalt 200 mg film-coated tablets Trobalt 300 mg film-coated tablets Trobalt 400 mg film-coated tablets Retigabine
Trobalt er til oral anveldese.
Trobalt is for oral use.
Trobalt er tril oral anvendelse.
Trobalt is for oral use.
Trobalt kan påvirke hjerterytmen.
Trobalt can affect heart rhythm.
Trobalt kan tages med eller uden mad (se pkt.
Trobalt may be taken with or without food (see section 5.2).
Trobalt kan øge varigheden af anæstesi induceret af visse anæstetika (f.eks. thiopentalnatrium, se pkt.
Trobalt may increase the duration of anaesthesia induced by some anaesthetics (for example thiopental sodium; see section 5.1).
Trobalt skal som andre antiepileptika seponeres gradvist for at minimere risikoen for anfald som følge af seponeringen.
Trobalt must be withdrawn gradually to minimise the potential for rebound seizures.
Trocoxil 6 mg tyggetabletter til hunde Trocoxil 20 mg tyggetabletter til hunde Trocoxil 30 mg tyggetabletter til hunde Trocoxil 75 mg tyggetabletter til hunde Trocoxil 95 mg tyggetabletter til hunde Mavacoxib
Trocoxil 6 mg chewable tablets for dogs Trocoxil 20 mg chewable tablets for dogs Trocoxil 30 mg chewable tablets for dogs Trocoxil 75 mg chewable tablets for dogs Trocoxil 95 mg chewable tablets for dogs Mavacoxib
Trocoxil gives i en dosis a 2 mg pr. kg legemsvægt umiddelbart inden eller sammen med hundens hovedmåltid.
Trocoxil is given at a dose of 2 mg per kilogram body weight, immediately before or with the dog’s main meal.
Trocoxil skal gives umiddelbart inden eller sammen med hundens hovedmåltid.
Trocoxil should be given immediately before or during the animal’s main meal.
Trocoxil tilhører en gruppe af lægemidler, der kaldes non-steroide anti-inflammatoriske lægemidler (NSAID’ere), som anvendes til behandling af smerter og betændelse.
Trocoxil belongs to a group of medicines called Non-steroidal Anti-inflammatory drugs (NSAIDs) which are used to treat pain and inflammation.
trods optimal antihypertensiv behandling
despite optimal antihypertensive therapy
troleandomycin, clarithromycin eller erythromycin (medicin til behandling af bakterieinfektioner)
troleandomycin, clarithromycin, or erythromycin (medicines for treatment of bacterial infections),
Trombin er et af de stoffer, der medvirker ved størkningsprocessen, og når det bindes til PAR-1 receptoren, bliver blodpladerne "klæbrige", så blodproppen lettere kan dannes.
Thrombin is one of the substances involved in the clotting process, and when it attaches to the PAR-1 receptor it causes the platelets to become ‘sticky’, helping the blood clot to form.
Trombin er nødvendigt for blodets størkning (koagulation).
Thrombin is essential for blood clotting.
Trombin spiller en central rolle i blodkoaguleringsprocessen.
Thrombin is central to the process of blood clotting.
Trombin spiller en central rolle i den trombotiske proces ved at spalte fibrinogen til fibrinmonomerer og ved at aktivere faktor XIII til faktor XIIIa, således at fibrin danner et kovalent krydsbundet netværk, som stabiliserer tromben.
Thrombin plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross- linked framework that stabilises the thrombus.
Trombo-
Neutropeniab,
Trombo- cytopeni
Thrombo- cytopenia
Trombo- cytopenia
Thrombo- cytopeniaa
Trombocitopenia (< 80 x 109/l), anemia (hemoglobina < 4,5 g/dl)3
Thrombocytopenia (< 80 x 109/l), anaemia (haemoglobin < 4.5 g/dl)3
Trombocyt
disorders
Trombocyt
immune-all
Trombocyt
immune-alle
Trombocyt
Immuno
Trombocyt
openia
Trombocyt
penia
Trombocyt
Thromboc
Trombocyt
Thrombocy
Trombocyt
Thrombocyto
Trombocyt
ystem
Trombocyt openi11
Thrombocytopeni a11
Trombocyt-abnormiteter af Grad 3 eller Grad 4, herunder trombocytopeni-bivirkninger blev set hos 14 % af de patienter, der fik TMZ.
Grade 3 or Grade 4 thrombocyte abnormalities, including thrombocytopenic events were observed in 14 % of the patients who received TMZ.
Trombocyt-abnormiteter af Grad 3 eller Grad 4, herunder trombocytopeni-bivirkninger, blev set hos 14 % af de patienter, der fik TMZ.
Grade 3 or Grade 4 thrombocyte abnormalities, including thrombocytopenic events were observed in 14 % of the patients who received TMZ.
Trombocyt-abnormiteter af Grad 3 eller Grad 4, inklusiveherunder trombocytopeni-bivirkninger blev set hos 14 % af de patienter, der fik TMZ.
Grade 3 or Grade 4 thrombocyte abnormalities, including thrombocytopenic events were observed in 14 % of the patients who received TMZ.
TROMBOCYTAGGREGATIONSHÆMMENDE MIDLER
PLATELET AGGREGGATION INHIBITORS
Trombocytfunktionen er genoprettet i løbet af 60 minutter efter standsning af infusionen.
Platelet function is restored within 60 minutes of stopping the infusion.
Trombocytfunktionshæmmere skal seponeres som foreslået i fabrikantens produktresumé.
Platelet aggregation inhibitors should be discontinued as suggested by the manufacturer’s prescribing information.
TROMBOCYTHÆMMENDE MIDLER
ANTIPLATELETS
trombocyto
Common:
trombocyto
ytopenia
trombocyto peni, anæmi og leukopeni
Thrombocytopenia, anaemia and leukopenia
Trombocyto peni11
Thrombocytope nia11
Trombocyto- peni, anæmi, leukopeni
Hypertension; Lymphocele
Trombocyto- peni, anæmi, leukopeni
nutrition disorders
Trombocyto- peni, anæmi, lymfadenopati
Thrombocyto penia, anaemia, lymphadenop athy
Trombocyto- peni, leukopeni, eosinofili
Thrombocytopenia, leucopenia, eosinophilia
Trombocytop eni11
Thrombocytopenia11
Trombocytope
Thrombocyt
Trombocytope
Thrombocyto
Trombocytope ni
Thrombocyto- penia
Trombocytope ni
Thrombocytopenia Leukocytosis
Trombocytope ni11
Thrombocyto penia11
Trombocytope ni11
Thrombocytopeni a11
Trombocytopeni
anaemia
trombocytopeni
cases of
trombocytopeni
Common:
Trombocytopeni
Immune system disorders
trombocytopeni
immune-alle
trombocytopeni
openia with
Trombocytopeni
Thrombocytopaenia
Trombocytopeni
Thrombocytopenia11
Trombocytopeni (2)
Thrombocytopenia (2)
trombocytopeni (< 100.000 celler/mm3) protrombintid > 1,2 gange kontrol eller International Normaliseret Ratio (INR) ≥ 2,0 svær hypertension (systolisk blodtryk > 200 mm Hg eller diastolisk blodtryk > 110 mm Hg under antihypertensiv behandling)
thrombocytopenia (< 100,000 cells/mm3) prothrombin time > 1.2 times control, or International Normalized Ratio (INR) ≥ 2.0 severe hypertension (systolic blood pressure > 200 mm Hg or diastolic blood pressure > 110 mm Hg on antihypertensive therapy)
Trombocytopeni (for lavt antal blodplader), leukopeni (for lavt antal hvide blodlegemer), granolytopeni (for lavt indhold af granulocytter, en type hvide blodlegemer), konjunktivitis (betændelse i den membran, der dækker øjets forreste halvdel), corneauklarhed (tilsløring af hornhinden, det gennemsigtige lag foran pupillen), keratitis (betændelse i hornhinden), lysfølsomhed og øjensmerter er også almindelige (optræder hos mellem 1 og 10 patienter ud af 100).
Thrombocytopenia (low blood platelet counts), leucopenia (low white blood cell counts), granulocytopenia (low levels of granulocytes, a type of white blood cell), conjunctivitis (inflammation of the membrane that lines the eyelid), corneal opacity (clouding of the cornea, the transparent layer in front of the pupil), keratitis (inflammation of the cornea), photophobia (increased sensitivity of the eyes to light) and eye pain are also common (seen in between 1 and 10 patients in 100).
Trombocytopeni (G3/4: 0,6 %) Febril neutropeni
Thrombocytopenia (G3/4: 3%)
Trombocytopeni (G3/4: 1,6 %);
135 (32.1)
Trombocytopeni (G3/4: 1,6 %);
Thrombocytopenia (G3/4: 0.6%);
Trombocytopeni (G3/4: 1,6 %);
Thrombocytopenia (G3/4: 1.6%);
Trombocytopeni (G3/4: 3 %)
Thrombocytopenia (G3/4: 0.6%); Febrile neutropenia
Trombocytopeni (G3/4: 4,0%);
Thrombocytopenia (G3/4: 4.0%);
Trombocytopeni (G3/4: 5,2 %)
Thrombocytopenia (G3/4: 4.0%);
Trombocytopeni (G3/4: 8,8%); Febril neutropeni
Febrile neutropenia
Trombocytopeni (G4: 0,2 %)
Thrombocytopenia (G4: 0.2%)
Trombocytopeni (G4: 0,5 %)
Thrombocytopenia (G4: 0.5%)
Trombocytopeni (i visse tilfælde med reversibelt fald i trombocyttal til under 5.000/mm³).
Thrombocytopenia (in some cases reversible platelet counts less than 5000 mm3).
trombocytopeni (lavt antal blodplader)
thrombocytopenia (low blood platelet counts);
Trombocytopeni (lavt antal blodplader)
Thrombocytopenia (low number of blood platelets)
Trombocytopeni (lavt antal blodplader)
Thrombocytopenia (low platelet count)
Trombocytopeni (meget almindelig).
Thrombocytopenia (very common).
Trombocytopeni (nogle meget sjældne tilfælde var svære med trombocyttal under 5.000 per mm3).
Thrombocytopenia (some very rare cases were severe with platelet counts less than 5,000 per mm3).
Trombocytopeni (nogle meget sjældne tilfælde var svære med trombocyttal under 5.000 per mm3).
Thrombocytopenia (some very rare cases were severe with platelet counts less than 5.000 per mm3).
Trombocytopeni < 25.000/mm3
Thrombocytopenia < 25,000/mm3
Trombocytopeni af grad 3 eller højere forekom hos 2,6 % af patienterne i ONIVYDE + 5-FU/LV- gruppen og hos 0 % i 5-FU/LV-gruppen.
Grade 3 or higher thrombocytopenia occurred in 2.6% of patients treated with ONIVYDE+5-FU/LV and 0% in patients treated with 5-FU/LV.
Trombocytopeni blev rapporteret hos 10 bivalirudin-behandlede patienter, som deltog i ACUITY- undersøgelsen (0,1 %).
Thrombocytopenia was reported in 10 bivalirudin-treated patients participating in the ACUITY study (0.1%).
Trombocytopeni eller funktionelle trombocytaggregation defekter
Thrombocytopenia or functional platelet defects
Trombocytopeni eller koagulationsdefekter;
Thrombocytopenia or coagulation defects;
Trombocytopeni er blevet indberettet hos patienter, der fik filgrastim (frekvens: almindelig).
Thrombocytopenia has been reported commonly in patients receiving filgrastim.
Trombocytopeni Febril neutropeni Anæmi Pancytopeni Granulocytopeni
Thrombocytopenia Febrile neutropenia Anaemia Pancytopenia Granulocytopenia
Trombocytopeni forbundet med kronisk hepatitis C (HCV)
Chronic hepatitis C (HCV) associated thrombocytopenia
Trombocytopeni forekom hos 27,0 % af patienterne, som fik Pom + LD-Dex, og hos 26,8 % af patienterne, som fik HD-Dex.
Thrombocytopenia occurred in 27.0% of patients who received Pom + LD-Dex, and 26.8% of patients who received HD-Dex.
Trombocytopeni forekommer typisk mellem 5. og 21. dag efter behandlingsstart med enoxaparinnatrium.
Thrombocytopenia typically occurs between the 5th and the 21st day following the beginning of treatment with enoxaparin sodium.
Trombocytopeni hos patienter med positiv in vitro-aggregationstest ved tilstedeværelse af enoxaparin.
Thrombocytopenia in patients with a positive in-vitro aggregation test in the presence of enoxaparin,
Trombocytopeni Leukopeni/neutropeni Leukocytose ikke andetsteds klassificeret
Thrombocytopenia Leukopenias/neutrop enia
Trombocytopeni Neutropeni Anæmi Lymfopeni
Thrombocytopenia Neutropenia Anaemia Lymphopenia
Trombocytopeni og immunogenicitet relateret til GP IIb/IIIa-hæmmere
Thrombocytopenia and Immunogencity related to GP IIb/IIIa inhibitors
Trombocytopeni og neutropeni
Thrombocytopenia and Neutropenia
Trombocytopeni var grad 3 eller 4 hos 20,7 % af patienterne, som fik Pom + LD-Dex, og hos 24,2 %, som fik HD-Dex.
Thrombocytopenia was Grade 3 or 4 in 20.7% of patients who received Pom + LD-Dex and in 24.2% who received HD-Dex.
trombocytopeni  lavt niveau af blodplader (fremgår af dine blodprøver) – dette kan føre til blødning
low level of platelets (thrombocytopenia) shown in blood tests – this may lead to bleeding
trombocytopeni  lavt niveau af blodplader (fremgår af dine blodprøver)  dette kan føre til blødning
low level of platelets (thrombocytopenia) shown in blood tests – this may lead to bleeding
Trombocytopeni#
Thrombocytopenia#
Trombocytopeni*
Thrombocytopenia
Trombocytopeni**
Thrombocytopaenia
trombocytopeni*, e
thrombocytopaenia*, e
Trombocytopeni*, febril neutropeni, neutropeni*, leukopeni*, anæmi*, lymfopeni*
Thrombocytopenia*, Febrile neutropenia, Neutropenia*, Leukopenia*, Anaemia*, Lymphopenia
Trombocytopeni*, koagulopati*.
Thrombocytopenia*, coagulopathy*.
Trombocytopeni*, neutropeni*, anæmi*
Thrombocytopenia*, Neutropenia*, Anaemia
Trombocytopeni, anæmi
Thrombocytopenia, Anaemia
Trombocytopeni, eosinofili
Thrombocytopenia, eosinophilia
Trombocytopeni, Leukocytopeni, Neutropeni, Anæmi*
Thrombocytopenia, Leukocytopenia, Neutropenia, Anaemia
Trombocytopeni, leukopeni Pancytopeni
Thrombocytopenia, leukopenia
trombocytopeni, leukopeni, anæmi, eosinofili, lymfadenopati,
thrombocytopenia, leukopenia, anaemia, eosinophilia,
Trombocytopeni, leukopeni, hæmolyse*
Thrombocytopenia, Leukopenia, Haemolysis
Trombocytopeni, leukopeni, leukocytose, hæmoragisk diatese
thrombocytopenia, leukopenia, leukocytosis, haemorrhagic diathesis
Trombocytopeni, leukopeni, pancytopeni
Thrombocytopeni a; Leukopenia, Pancytopenia
Trombocytopeni, leukopeni, pancytopeni
Thrombocytopenia; Leukopenia, Pancytopenia
trombocytopeni, neutropeni (blodsygdomme)
thrombocytopenia, neutropenia (blood disorders)
Trombocytopeni, neutropeni og anæmi
Thrombocytopaenia, neutropaenia, and anaemia
trombocytopeni, neutropeni, anæmi, leukopeni
thrombocytopenia, neutropenia, anaemia, leukopenia
trombocytopeni, neutropeni, leukocytose, polycytæmi, lymfopeni
thrombocytopenia, neutropenia, leukocytosis, polycythaemia, lymphopenia
Trombocytopeni, neutropeni, leukopeni, lymfopeni
Thrombocytopenia, neutropenia, leukopenia, lymphopenia
Trombocytopeni, purpura, leukopeni, anæmi, methæmoglobinæmi, agranulocytose
Thrombocytopenia, purpura, leukopenia, anemia, methemoglobinemia, agranulocytosis
Trombocytopeni11
Thrombocyto penia11